Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Accured Expenses data on file, last reported at -$22.4 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 131.21% year-over-year to -$22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12.2 million (down 39.79% YoY) and the FY2025 annual result came in at $465000.0, down 85.68% from the prior year.
• Change in Accured Expenses eased to -$22.4 million in Q1 2026 per DNLI's latest filing, from $12.7 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $24.6 million in Q3 2024 and bottomed at -$32.2 million in Q2 2023.
• The 5-year median for Change in Accured Expenses is $1.9 million (2025), against an average of -$300941.2.
• The widest annual swing landed in 2023, when Change in Accured Expenses tumbled 649.17%; it then jumped 3249.59% in 2024.
• Tracing DNLI's Change in Accured Expenses over 5 years: stood at $4.0 million in 2022, then jumped by 255.43% to $14.3 million in 2023, then tumbled by 119.86% to -$2.8 million in 2024, then surged by 547.82% to $12.7 million in 2025, then slumped by 275.96% to -$22.4 million in 2026.
• Per Business Quant, the three latest DNLI Change in Accured Expenses figures stand at -$22.4 million (Q1 2026), $12.7 million (Q4 2025), and $1.9 million (Q3 2025).

Peer Comparison